Our Blog

Updated: Apr 5

4 April 2022, Cambridge, MA -- RS Oncology, LLC, (RSO) a biotechnical company focused on the treatment of patients with malignant pleural effusion and mesothelioma, announces the dosing of the first patient with RSO-021 as part of its first-in-human Phase 1/2 clinical trial (MITOPE) at the University Hospitals of Leicester in the U.K. RSO will be evaluating its novel treatment, RSO-021, against a specific mitochondrial enzyme regulating oxidative stress pathways in cancer cells.


This novel therapeutic approach has proven in pre-clinical studies to significantly reduce tumor burden in malignant mesothelioma and other cancer types by irreversibly binding and inhibiting a key enzyme in the antioxidant signaling network within the mitochondria of malignant cells.


“Our team is excited to begin patient dosing with our novel metabolic therapy. This is a significant milestone in developing a treatment for people suffering from this horrible disease,” stated CEO Jarrett Duncan. “We are eager to see activity of our drug in humans following our successful pre-clinical studies in multiple indications,” added COO and Head of Business Development, George Naumov, Ph.D.


Mesothelioma remains a lethal cancer lacking effective treatments, particularly in patients with relapsed disease. This exciting study of a first in class PRX3 inhibitor is hoped to show promising signals that could lead to development of a new approach to tackle this cancer.” said the clinical investigator from Leicester Hospital, Professor Dean Fennell, FRCP FRSB.

About MITOPE clinical trial

The MITOPE Phase 1/2 clinical trial is a first-in-human study that will evaluate RSO-021 as a treatment for patients suffering from MPE and mesothelioma. RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage. The MITOPE trial is planned to open in six UK-based clinical institutions and will be recruiting patients in collaboration with Mesothelioma UK. For more MITOPE information review https://www.mesothelioma.uk.com/clinical-trials/ or contact MITOPE@rsoncology.com. The study is supported by NIHR.


About RS Oncology

RSO is a clinical stage biotechnology company based in Cambridge, Massachusetts with a mission to eradicate mesothelioma worldwide through new science and an innovative business model. The lead program RSO-021 is currently focused on development of novel therapies that modulate mitochondrial pathways that drive diseases of oxidative stress for treatment of malignant pleural effusion and malignant mesothelioma.


About NIHR

The National Institute for Health Research is UK's largest funder of health and care research. The NIHR: funds, supports and delivers high quality research that benefits the UK National Health System, public health and social care; engages and involves patients, caregivers and the public in order to improve the reach, quality and impact of research; attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future; invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services; partners with other public funders, charities and industry to maximize the value of research to patients and the economy.



For Corporate Inquiries: Jarrett Duncan, CEO, RS Oncology j.duncan@rsoncology.com


For Media Inquiries:  Nichole Pfeiffer Hicks, Patient Advocacy, RS Oncology n.hicks@rsoncology.com



RS Oncology, LLC announces the initiation of its MITOPE Phase 1/2 clinical trial for the treatment of patients with malignant pleural effusion and mesothelioma


Cambridge, Mass., 24 February 2022 -- RS Oncology, LLC, (RSO) a biotechnology company focused on the treatment of patients with malignant pleural effusion (MPE) and mesothelioma, announces the opening of its first-in-human Phase 1/2 clinical trial (MITOPE) at the University Hospitals of Leicester in the U.K. RSO will be evaluating its novel treatment, RSO-021, against mitochondrial PRX3 enzyme, regulating oxidative stress pathways in cancer cells.

This novel therapeutic approach has proven in pre-clinical studies to significantly reduce tumor burden in malignant mesothelioma and other cancer types by irreversibly binding and inhibiting PRX3 enzyme in the antioxidant signaling network within the mitochondria of malignant cells.


“The RSO team is excited to begin treating patients at The University of Leicester, U.K. The MITOPE trial is a culmination of substantial innovative work completed by our academic collaborators at University of Vermont, College of Medicine and Wake Forest School of Medicine. This trial is an important step in improving treatment options for people suffering from malignant pleural effusion and mesothelioma,” stated Jarrett Duncan, RS Oncology’s CEO. “Our novel therapeutic approach has shown pre-clinical efficacy and safety in nearly a dozen cancer types. We eagerly await the clinical data validating RSO-021 as a safe and effective treatment option for patients with cancer. This novel treatment is desperately needed in the clinical community as patients lack effective second line treatment options,” added COO and Head of Business Development, George Naumov.

About MITOPE clinical trial

The MITOPE Phase 1/2 clinical trial is a first-in-human study that will evaluate RSO-021 as a treatment for patients suffering from MPE and mesothelioma. RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme PRX3 (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage. The MITOPE trial is planned to open in six UK-based clinical institutions and will recruit patients with the help of Meso UK. For more MITOPE information review https://www.mesothelioma.uk.com/clinical-trials/ or contact MITOPE@rsoncology.com. The study is supported by NIHR.


About RS Oncology

RSO is a clinical stage biotechnology company based in Cambridge, Massachusetts with a mission to eradicate mesothelioma worldwide through new science and an innovative business model. The lead program, RSO-021, is currently focused on development of novel therapies that modulate mitochondrial pathways that drive diseases of oxidative stress for treatment of malignant pleural effusion and malignant mesothelioma.



About NIHR

The National Institute for Health Research is UK's largest funder of health and care research. The NIHR: funds, supports and delivers high quality research that benefits the UK National Health System, public health and social care; engages and involves patients, caregivers and the public in order to improve the reach, quality and impact of research; attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future; invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services; partners with other public funders, charities and industry to maximize the value of research to patients and the economy.



For Corporate Inquiries: Jarrett Duncan, CEO, RS Oncology j.duncan@rsoncology.com

For Media Inquiries:  Nichole Pfeiffer Hicks, Patient Advocacy, RS Oncology n.hicks@rsoncology.com


RS Oncology, LLC, announces UK Medicines and Healthcare Regulatory Agency’s clinical trial acceptance of new drug, RSO-021, for treatment of Pleural Effusion and Mesothelioma


Cambridge, MA, October 1, 2021 ---- RS Oncology, LLC, (RSO) a biotechnical company focused on the treatment of patients with pleural effusion and mesothelioma, has announced acceptance of their novel drug, RSO-021, for use in a Phase 1/2 clinical trial by the Medicines and Healthcare Regulatory Agency in the UK.


RSO-021 therapy has proven to significantly reduce pre-clinically tumor burden in malignant mesothelioma and other cancer types by inhibiting three key enzymes in the antioxidant signaling network within the mitochondria. Covalent adduction of the active site of a key mitochondrial enzyme by RSO-021 inactivates the peroxidase activity of the enzymes leading to accumulation of hydrogen peroxide to levels incompatible with tumor cell survival, while preserving healthy normal cells. RSO-021 is being developed for the treatment of malignant pleural effusion (MPE) via intrapleural (IP) installation in patients suffering from mesothelioma, breast cancer and other indications causing MPE.


“We’re excited about RSO-021 as a novel metabolic therapy. This clinical trial is an important step in improving treatment for people living with this aggressive cancer,” said RS Oncology CEO and General Counsel, Jarrett Duncan. “RSO-021, the result of a collaboration between RSO, the University of Vermont Cancer Center and Wake Forest University School of Medicine, shows tremendous promise. The treatment has shown pre-clinical efficacy in nearly a dozen different indications, signifying broad applicability and therapeutic potential for cancer therapy.” “Most notably, treatments using this unique mechanism of action can be guided by a companion diagnostic, identifying patients with sufficiently dysregulated metabolic pathways prone to respond to this novel therapeutic approach.” added COO and Head of business development, George Naumov, Ph.D.



RS Oncology, LLC is a preclinical stage biotechnology company based in Cambridge, Massachusetts and London, UK with a mission to eradicate mesothelioma worldwide through new science and an innovative business model. The lead program is currently focused on development of novel therapies that modulate mitochondrial pathways that drive diseases of oxidative stress for treatment of malignant pleural effusion and malignant mesothelioma.

1
2